Theravance Biopharma, Inc. (TBPH)
Automate Your Wheel Strategy on TBPH
With Tiblio's Option Bot, you can configure your own wheel strategy including TBPH - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TBPH
- Rev/Share 1.59
- Book/Share 4.6057
- PB 4.1294
- Debt/Equity 0.1917
- CurrentRatio 9.4821
- ROIC -0.0292
- MktCap 963743913.0
- FreeCF/Share 4.8195
- PFCF 3.9582
- PE 58.8167
- Debt/Assets 0.1073
- DivYield 0
- ROE 0.0818
- Rating B-
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 4
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | TBPH | Oppenheimer | -- | Outperform | -- | $27 | Dec. 3, 2025 |
| Initiation | TBPH | B. Riley Securities | -- | Buy | -- | $28 | Sept. 12, 2025 |
News
Why Theravance Biopharma (TBPH) is a Top Momentum Stock for the Long-Term
Published: January 06, 2026 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Wall Street Analysts Believe Theravance Bio (TBPH) Could Rally 42.15%: Here's is How to Trade
Published: December 22, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Theravance Bio (TBPH) points to a 42.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Theravance Biopharma (TBPH) is a Great Momentum Stock: Should You Buy?
Published: December 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Does Theravance Biopharma (TBPH) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
Does Theravance Bio (TBPH) Have the Potential to Rally 30.64% as Wall Street Analysts Expect?
Published: December 05, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 30.6% upside potential for Theravance Bio (TBPH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Why Theravance Biopharma (TBPH) is a Top Growth Stock for the Long-Term
Published: December 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025
Published: November 20, 2025 by: PRNewsWire
Sentiment: Neutral
DUBLIN , Nov. 20, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that it will host a virtual key opinion leader (KOL) investor event on Monday, December 8, 2025 at 10:30 AM ET. To register, click here.
Read More
Theravance Biopharma (TBPH) is a Top-Ranked Growth Stock: Should You Buy?
Published: November 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Theravance's Q3 Earnings Surpass Estimates, Revenues Match
Published: November 11, 2025 by: Zacks Investment Research
Sentiment: Positive
TBPH delivers a third-quarter profit, beating estimates, and 19% revenue growth, fueled by rising collaboration income from Viatris related to Yupelri sales.
Read More
CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Buy?
Published: October 30, 2025 by: Zacks Investment Research
Sentiment: Neutral
CorMedix and Theravance take sharply different routes to small-cap biotech growth - one fueled by sales traction, the other by pipeline promise.
Read More
Theravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous System
Published: October 29, 2025 by: PRNewsWire
Sentiment: Neutral
Ampreloxetine clinical development program to be featured in four presentations at the upcoming International Symposium on The Autonomic Nervous System Topline results from the ongoing Phase 3 CYPRESS study of ampreloxetine anticipated in Q1 2026 DUBLIN , Oct. 29, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that it will be participating at the 36th International Symposium on the Autonomic Nervous System, organized by the American Autonomic Society (AAS), taking place November 5-8, 2025, in Clearwater Beach, FL. The Company will have one platform presentation and three poster presentations on its clinical development program for ampreloxetine, a potential …
Read More
Theravance Bio (TBPH) Up 9.8% Since Last Earnings Report: Can It Continue?
Published: September 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock?
Read More
Theravance's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y
Published: August 13, 2025 by: Zacks Investment Research
Sentiment: Positive
TBPH posts better-than-expected second-quarter 2025 results, boosted by Yupelri sales and licensing gains.
Read More
5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats
Published: July 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Innovation is at its peak in the Zacks Medical-Drugs industry. CPRX, ZVRA, TBPH, ALDX and LRMR may prove to be good additions to one's portfolio.
Read More
TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Theravance to sell its remaining Trelegy royalty interest to GSK for $225M, with shares jumping 22% on the deal's announcement.
Read More
Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million
Published: June 02, 2025 by: PRNewsWire
Sentiment: Neutral
Definitive agreement to result in one-time $225 million cash payment Theravance Biopharma retains rights to up to $150 million in milestones from Royalty Pharma on Trelegy Ellipta net sales in 2025 and 2026, requiring minimal to no growth over 2024 actuals to be achieved $225 million from royalty transaction announced today, in addition to the $1.1 billion upfront received in 2022 , and up to $200 million in milestones (of which $50 million was received in 2025), brings total potential lifetime value from Trelegy Ellipta monetization efforts to $1.525 billion First outcome from Strategic Review Committee's ongoing efforts to maximize …
Read More
Theravance's Q1 Loss Wider Than Expected, Revenues Rise Y/Y
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Neutral
TBPH reports weaker-than-expected first-quarter 2025 results. Collaboration revenues from Viatris rise year over year.
Read More
Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress
Published: May 09, 2025 by: PRNewsWire
Sentiment: Neutral
DUBLIN , May 9, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced presentation of analyses of its previous Phase 3 program evaluating ampreloxetine, an investigational medicine for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) at the International MSA Congress, taking place May 9-11 in Boston, Massachusetts. A subgroup analysis selected as a platform presentation focused on patients with Multiple System Atrophy (MSA) in the REDWOOD 0170 study (NCT03829657), an international phase 3, placebo-controlled, double-blind, randomized withdrawal trial, designed to demonstrate clinical worsening in those assigned to placebo.
Read More
Theravance to Present Analyses of Ampreloxetine and Neurogenic Orthostatic Hypotension at the 2025 International MSA Congress
Published: April 28, 2025 by: PRNewsWire
Sentiment: Neutral
DUBLIN , April 28, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that analyses of the initial Phase 3 program of ampreloxetine (Studies 169 and 170) will be presented at the International MSA Congress, taking place May 9-11, 2025, in Boston, Massachusetts. These analyses support the Company's understanding of ampreloxetine's highly selective mechanism of action and potential to address symptoms of neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA).
Read More
Theravance Biopharma to Present New Ampreloxetine Analyses in Neurogenic Orthostatic Hypotension (nOH) at the 77th Annual Meeting of the American Academy of Neurology
Published: March 27, 2025 by: PRNewsWire
Sentiment: Neutral
DUBLIN , March 27, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced new analyses of the initial Phase 3 program of ampreloxetine (Studies 169 and 170) supporting its selective and differentiated pharmacodynamic profile will be presented at the 77th Annual Meeting of the American Academy of Neurology (AAN) Meeting, taking place April 5-9, 2025, in San Diego, California. Results from these initial studies led to the initiation of a Phase 3 confirmatory study (CYPRESS Study 197) addressing nOH in patients with multiple system atrophy, which is currently ongoing.
Read More
Theravance Biopharma, Inc. (TBPH) Q4 2024 Earnings Call Transcript
Published: February 26, 2025 by: Seeking Alpha
Sentiment: Neutral
Theravance Biopharma, Inc. (NASDAQ:TBPH ) Q4 2024 Earnings Conference Call February 26, 2025 5:00 PM ET Company Participants Rick Winningham – Chief Executive Officer Rhonda Farnum – Chief Business Officer Aziz Sawaf – Chief Financial officer Aine Miller – Head-Development Conference Call Participants Douglas Tsao – H.C. Wainwright Julian Harrison – BTIG David Risinger – Leerink Partners Operator Ladies and gentlemen, good afternoon.
Read More
Theravance Biopharma to Participate in an Upcoming Investor Conference
Published: February 20, 2025 by: PRNewsWire
Sentiment: Neutral
DUBLIN , Feb. 20, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will present at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4 at 11:50 am EST (8:50 am PST/4:50 pm GMT) and will be hosting in-person meetings with the investment community at the conference. Webcast of the event may be accessed by visiting Theravance.com, under the Investors section, Events and Presentations.
Read More
Theravance Biopharma to Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
Published: February 12, 2025 by: PRNewsWire
Sentiment: Neutral
DUBLIN, Ireland , Feb. 12, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its fourth quarter and full year 2024 financial results and provide a business update after market close on Wednesday, February 26, 2025. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm EST (2:00 pm PST/10:00 pm GMT) that day.
Read More
About Theravance Biopharma, Inc. (TBPH)
- IPO Date 2014-05-16
- Website https://www.theravance.com
- Industry Biotechnology
- CEO Rick E. Winningham
- Employees 97